Here’s an article that caught my eye in a US publication. It’s about Genzyme’s potential acquisition giving jitters to patients. Quod erat demonstrandum.
Here’s an article that caught my eye in a US publication. It’s about Genzyme’s potential acquisition giving jitters to patients. Quod erat demonstrandum.